

UC Irvine

UC Irvine Previously Published Works

Title

A Simple DNzyme-Based Fluorescent Assay for *Klebsiella pneumoniae*

Permalink

<https://escholarship.org/uc/item/1vb2k2kx>

Journal

ChemBioChem, 20(7)

ISSN

1439-4227

Authors

Ali, M Monsur
Slepenkin, Anatoly
Peterson, Ellena
et al.

Publication Date

2019-04-01

DOI

10.1002/cbic.201800701

Peer reviewed



Published in final edited form as:

Chembiochem. 2019 April 01; 20(7): 906–910. doi:10.1002/cbic.201800701.

A simple DNAzyme-based fluorescent assay for *Klebsiella pneumoniae*

M. Monsur Ali^a, Anatoly Slepkin^b, Ellena Peterson^b, Weian Zhao^c

^aBiointerfaces Institute, McMaster University, 1280 Main St. W., Hamilton, ON L8S 4K1 (Canada)

^bDepartment of Pathology and Laboratory Medicine, University of California, Irvine, California 92697, USA.


^c1] Department of Pharmaceutical Sciences, Sue and Bill Gross Stem Cell Research Center, Edwards Lifesciences Center for Advanced Cardiovascular Technology, and the Department of Biomedical Engineering, University of California-Irvine, 845 Health Sciences Road, Irvine, California 92697, USA

Abstract

Pathogenic bacteria pose a serious public health threat. Rapid and cost effective detection of such bacteria remains a major challenge. Here, we present a DNAzyme-based fluorescent paper sensor for *Klebsiella pneumoniae*. The DNAzyme was generated by an in vitro selection technique to cleave a fluorogenic DNA-RNA chimeric substrate in the presence of *K. pneumoniae*. The DNAzyme was printed on a paper substrate in a 96 well format to serve as mix-and-read fluorescent assay which exhibited a limit of detection (LOD) 10^5 CFUs/mL. It was evaluated with 20 strains of clinical bacterial isolates and the DNAzyme produced the desired fluorescence signal with the samples of *K. pneumoniae*, regardless of their source or drug resistance. The assay is simple to use, rapid, inexpensive, avoids complex procedures of sample preparation and equipment. We believe, this DNAzyme-based fluorescent assay has potential for practical applications to identify *K. pneumoniae*.

Graphical Abstract

Lighting up bacteria with DNAzyme. Infection of pathogenic bacteria remains a major health threat. Convenient detection of such pathogens plays a key role in protecting health and loss of economy. Herein, we present a DNAzyme that produce fluorescence signal in presence of *K. pneumoniae*.



Keywords

DNAzyme; Fluorogenic; *Klebsiella pneumoniae*; Paper sensor; Pathogenic bacteria

Infectious diseases remain a major cause of morbidity and mortality throughout the world.^[1] Besides the loss of lives, it also imposes a huge economic burden in our society.^[1b,c,2] Additionally, the emergence of multidrug resistant bacteria has become a major public health concern. According to the Centers for Disease Control and Prevention (CDC), at least 2 million people in the United States alone are infected with drug resistant bacteria and 23,000 people die from these infections each year.^[3] In 2017, the World Health Organization (WHO) published its first ever list of antibiotic-resistant “priority pathogens” that pose the greatest threat to human health and categorized them into critical, high and medium priority.^[4] *K. pneumoniae* has been included in the critical group because of its rapid development of resistance towards multiple antibiotics.^[4] *K. pneumoniae* is a gram negative bacteria and is a leading cause of respiratory tract, urinary tract, and blood stream infections.^[5] Both carbapenemase and extended-spectrum beta-lactamase producing *K. pneumoniae* have created a critical health concern because of their resistance to a wide spectrum of beta lactam antibiotics.^[5,6] Therefore, a rapid and selective assay for *K. pneumoniae*, in particular resistant isolates, can afford early intervention and thus play a vital role in the treatment and spread of these resistant strains.

The current standard methods for confirming the presence of carbapenemase producing *K. pneumoniae* (KPC) are culture followed by susceptibility testing.^[7] Standard susceptibility testing can be further followed with molecular methods such as polymerase chain reaction (PCR) to confirm the presence of target genes. All these procedures are technically complex and require expensive equipment and highly trained personnel. On the other hand, immunoassays deliver relatively fast results. However, for the most part these methods are

expensive, not sensitive or specific.^[8] Therefore, there is still a need for new methods that can circumvent these limitations and can be used in resource deprived areas.

Recently, RNA-cleaving fluorogenic DNazymes (RFDs) have emerged as potential candidates to develop bacterial bioassays.^[9] These RFDs catalyze the cleavage of a DNA-RNA chimeric substrate at a single ribonucleotide junction embedded in a DNA sequence. The ribonucleotide is flanked by a fluorophore (F) and a quencher (Q), thus exhibits minimal fluorescence before the cleavage reaction because of the close proximity of F and Q. However, upon interaction with the target molecule in the complex crude extra/intra cellular mixture of the bacteria, the DNzyme is activated and cleaves the substrate to separate F from Q and generates a high fluorescence signal (Figure 1A). RFDs are generated by an in vitro selection procedure using a random DNA library and crude extra/intra cellular mixtures of target bacteria including *E. coli* and *C. difficile*.^[9] Once the DNazymes are obtained, they can readily be used to formulate a mix-and-read fluorescent assay.^[10] Advantageously, these RFDs can also be employed to develop colorimetric assays^[11] including integration with isothermal secondary amplification.^[12]

In this study, we aimed to generate a DNzyme for *K. pneumoniae* and developed a paper-based assay in a 96 well format that could be used in point of care and low-resource settings. The DNzyme was generated by our previously reported in vitro selection technique^[9] using a random DNA library and a mixture of cell lysates composed of a mixture of carbapenam resistant *K. pneumoniae* which are listed in Table S1 in the supporting information (SI). The DNA library and the relevant sequences used for the in vitro selection are depicted in Figure 1B. We used a pool of cell lysates of *K. pneumoniae* strains as a complex target in the selection assuming that the DNazymes obtained after the selection would respond to all *K. pneumoniae* rather than responding to a specific strain.

The DNA library covalently linked to the substrate (DL-FS) was mixed with cell lysates and incubated at room temperature for the cleavage reaction. The cleaved DNA molecules were purified by denaturing polyacrylamide gel electrophoresis (dPAGE) and amplified by PCR (See experimental section in the SI for details). This PCR enriched population was covalently attached to FS and applied to the next round of selection. The selection and enrichment process was repeated until a significant amount of cleaved product was obtained. A representative dPAGE image of the selection progress is shown in Figure 1C. To achieve selectivity, negative selection was applied in every two rounds of selection using a cell lysate mixture of carbapenam sensitive *K. pneumoniae*, *E. coli* and *B. subtilis*. After 11 rounds of selection, the enriched population was used in deep sequencing.

The top 10 sequences (Figure S2A in the SI) were chemically synthesized and tested for their cleavage performance with the reaction buffer (control) and cell lysate of carbapenam resistant *K. pneumoniae* (test). The cleavage results indicated that some DNzyme candidates performed well without producing any background cleavage in the reaction buffer alone (Figure S2B in ESI). They cleave the substrate only in the presence of the *K. pneumoniae* cell lysate. Next, some DNazymes with good cleavage activity were further tested for selectivity with *E. coli* (EC), *B. subtilis* (BS), *L. monocytogenes* (LM) and *F. nucleatum* (FN). The results presented in Figure 2A revealed that DNzyme 6 (named RFD-

section). We found that some *K. pneumoniae* isolates produced the highest fluorescent signal compared to the other bacterial isolates. However, as seen in Figure 4, other bacterial isolates produced an equivalent fluorescence signal to the *K. pneumoniae* isolates, namely 441,443, 451 and 453. This may be due to other bacteria producing a high amount of nucleases which randomly degrade the DNAzyme rather than cleaving the substrate in the designated cleavage site. To verify this hypothesis, we collected the cleavage reaction mixtures from each microzone and analyzed them by dPAGE (Figure 4C). The dPAGE analysis produced consistent results with the fluorescence data. However, we noticed that some bacteria produced high amount of nucleases evidenced by the disappearance of the full length DNAzyme bands (Sample ID 438 and 453). Since nuclease activity is a major challenge in developing DNA based assays or therapeutics, attempts have been made to overcome this issue by incorporating modified nucleotides.^[15] Our future work will also explore this option when developing DNAzymes.

It was also noticed that some *K. pneumoniae* strains (sample 446, 447 and 448) produced a somewhat lower fluorescent signal than others although the gel image showed almost similar cleavage products. We speculate that these strains may produce less target during culture thus causing slower cleavage reactions by the DNAzyme. It is important to note that the same samples were collected from the paper microzones to be analyzed by gel electrophoresis and it took significant time to collect the samples from the paper microzones. We assume that during the sample collection time the cleavage reactions continued to produce more cleavage products.

In summary we have generated a new fluorogenic DNAzyme by *in vitro* selection that catalyzes a fluorogenic substrate in the presence of *K. pneumoniae*. The DNAzyme is moderately specific in that it shows promise in being able to differentiate *K. pneumoniae* from other members of the Enterobacteriaceae, however, it was unable to differentiate susceptible isolates from carbapenem resistant isolates. With further improvement in specificity, this approach has the potential to provide a low cost, rapid method to identify these isolates once they are cultured.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The work was supported by National Institutes of Health (NIH)/ National Institute of Allergy and Infectious Diseases (NIAID) (1 R01 AI117061)

[**] Funding is provided by National Institutes of Health (NIH)/ National Institute of Allergy and Infectious Diseases (NIAID) (1 R01 AI117061)

References

- [1]. a) Klevens RM, Edwards JR, Richards CL Jr., Horan TC, Gaynes RP, Pollock DA, Cardo DM, Public Health Rep. 2007,122,160–166; [PubMed: 17357358] b) Fonkwo PN, EMBO Rep., 2008, S13–17; [PubMed: 18578017] c) Suhrcke M, Stuckler D, Suk JE, Desai M, Senek M, McKee M, Tsolova S, Basu S, Abubakar I, Hunter P, Rechel B, Semenza JC, PLoS One. 2011, 6, e20724;d)

- Osterholm MT, Engl N. *J. Med.* 2011, 364, 889–891;e) Scallan E, Hoekstra RM, Angulo FJ, Tauxe RV, Widdowson MA, Roy SL, Griffin PM, Emerg. Infect. Dis. 2011, 17, 7–15. [PubMed: 21192848]
- [2]. http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html
- [3]. <https://www.cdc.gov/drugresistance/index.html>
- [4]. <http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/>
- [5]. a) Khaertynov KS, Anokhin VA, Rizvanov AA, Davidyuk YN, Semyenova DR, Lubin SA, Skvortsova NN, *Front. Med.*, 2018, 5, 225; b) Jiao Y, Qin Y, Liu J, Li Q, Dong Y, Shang Y, Huang Y, Liu R, *Pathog. Glob. Health.* 2015, 109, 68–74. [PubMed: 25707874]
- [6]. a) Kurupati P, Chow C, Kumarasinghe G, Poh CL, *J. Clinic. Microbiol.* 2004, 42, 1337–1340.
- [7]. a) Hirsch EB, Tam VH, *J. Antimicrob. Chemother.* 2010, 65, 1119–1125; [PubMed: 20378670] b) Doern CD, Dunne WM Jr., C-A D Burnham, 2011, 49, 1143–1147; c) <https://www.cdc.gov/labtraining/training-courses/master/antimicrobial-susceptibility-testing-methods-ast.html>
- [8]. a) Baker CA, Rubinelli PM, Park SH, Ricke SC, *Crit Rev Microbiol.* 2016, 42, 656–675; [PubMed: 26016737] b) Vidic J, Manzano M, Chang CM, Jaffrezic-Renault N, *Vet Res.* 2017, 48, 11 [PubMed: 28222780]
- [9]. a) Ali MM, Aguirre SD, Lazim H, Li Y *Angew. Chem. Int. Ed. Engl.*, 2011, 50, 3751–3754; [PubMed: 21412961] b) Shen Z, Wu Z, Chang D, Zhang W, Tram K, Lee C, Kim P, Salena BJ, Li Y, *Angew. Chem. Int. Ed. Engl.*, 2016, 55, 2431–2434 [PubMed: 26676768]
- [10]. a) Aguirre SD, Ali MM, Salena BJ, Li Y, *Biomolecules*, 2013, 3, 563–577; [PubMed: 24970181] b) Aguirre SD, Ali MM, Kanda P, Li Y, *J. Vis. Exp.*, 2012, 63, e3961; c) Ali MM, Brown CL, Jahanshahi-Anbuhi S, Li Y, Brennan JD, *Scientific Reports*, 2017, 7, 12335.
- [11]. Tram K, Kanda P, Salena BJ, Huan S, Li Y, *Angew. Chem. Int. Ed. Engl.*, 2014, 53, 12799–12802; [PubMed: 25213464] e) Tram K, Manochery S, Feng Q, Chang D, Salena BJ, Li Y, *J. Vis. Exp.*, 2016, 115, e54546; c) Zheng L, Qia P, Zhang D, *Sensors & Actuators: B. Chemical*, 2018, 27642–27647
- [12]. a) Liu M, Zhang Q, Li Z, Gu J, Brennan JD, Li Y, *Nat Commun.*, 2016, 7, 12074; [PubMed: 27337657] b) Liu M, Zhang Q, Chang D, Gu J, Brennan JD, Li Y, *Angew. Chem. Int. Ed. Engl.* 2017, 56, 6142–6146 [PubMed: 28370773]
- [13]. a) Bernier B, *Canadian J Microbiol.*, 1958, 4 195–204; b) Bender H, Lechmann J, Wallenfells K, *Biochemica Biophysica Acta*, 1959, 36, 309–316
- [14]. a) Jahanshahi-Anbuhi S, Pennings K, Leung V, Liu M, Carrasquilla C, Kannan B, Li Y, Pelton R, Brennan JD, Filipe CD. *Angew. Chem. Int. Ed. Engl.*, 2014, 53, 6155–6158; [PubMed: 24764260] b) Hsieh PY, Ali MM, Tram K, Jahanshahi-Anbuhi S, Brown C, Brennan JD, Filipe CD, Li Y, *ChemBioChem*, 2017, 18, 502–505; [PubMed: 28090736] c) Kannan CB, Jahanshahi-Anbuhi S, Pelton RH, Li Y, Filipe CD, Brennan JD, *Anal. Chem.*, 2015, 87, 9288–9293; [PubMed: 26332017] c) Liu M, Hui CY, Zhang Q, Gu J, Kannan B, Jahanshahi-Anbuhi S, Filipe CD, Brennan JD, Li Y, *Angew. Chem. Int. Ed. Engl.*, 2016, 55, 2709–2713 [PubMed: 26748431]
- [15]. a) Schubert S, Gül DC, Grunert H-P, Zeichhardt H, Erdmann VA, Kurreck J, *Nucleic Acids Res.* 2003, 31, 5982–5992; [PubMed: 14530446] b) Chakravarthy M, Aung-Htut MT, Le BT, Veedu RN, *Sci Rep.* 2017, 7, 1613; [PubMed: 28487530] c) Ni S, Yao H, Wang L, Lu J, Jiang F, Lu A, Zhang G, *Int J Mol Sci.* 2017, 18, 1683; d) Gawande BN, Rohloff JC, Carter JD, Carlowitz IV, Zhang C, Schneider DJ, Janjic N, *Proc Natl Acad Sci U S A*, 2017 114, 2898–2903; [PubMed: 28265062] e) Kimoto M, Yamashige R, Matsunaga K, Yokoyama S, Hirao I, *Nat Biotechnol.* 2013, 31, 453–457 [PubMed: 23563318]




Figure 1.

A) Schematic illustration of the mode of action of the DNAzyme. The inactive DNAzyme with low fluorescence becomes activated upon binding to the target molecule present in the cell lysate and cleaves the substrate at the designated cleavage site rendering fluorescence signal enhancement. B) DNA library and related oligonucleotide sequences used in the in vitro selection process. FP: forward primer, RP1: reverse primer that was used in the first PCR to enrich the selected pool, RP2: second reverse primer used in the second PCR for large scale production of the DNA pool in each round. A20 is 20 deoxyadenosine separated from the primer by a C18 glycol linker (Spacer 9 of IDT catalog). FQ30: the fluorogenic substrate wherein F is fluorescein-dT (fluorophore), rA is riboadenosine that serves as cleavage junction, Q is dabcyle-dT (quencher). LT: ligation template used for enzymatic ligation of the library with FQ30. C) Fluorescent gel images of the progress of selection. The marker was prepared by treating a portion of the FS ligated library with NaOH as discussed in the experimental section. Uclv: uncleaved full length sequence, Clv: cleaved sequence in the positive selection.




Figure 2. DNAzymes with select bacteria. RB: reaction buffer, KP: *K. pneumoniae* (carbapenem resistant), EC: *E. coli*, BS: *B. subtilis*, LM: *L. monocytogenes*, FN: *F. nucleatum*. B) Test of ability of discrimination of RFD-KP6 with drug susceptible *K. pneumoniae* (KPS), carbapenem resistant *K. pneumoniae* (KPC) and extended spectrum beta lactamase producing *K. pneumoniae* (KP-ESBL). C) Real time fluorescence signaling performance of RFD-KP6.




Figure 3.

A) Design of paper sensor. B) Physical appearance of the paper device after printing of the DNAzyme. C) Cleavage and fluorescence signaling test of the paper device. D) Quantified fluorescence signal of C. E) Sensitivity test of RFD-KP6 with KPC with the paper microzone assay. Insert: fluorescent image of paper microzones with varying numbers of bacterial cells. The error bars are standard deviations of triplicate experiments. F) a representative denaturing gel




Figure 4.

Evaluation of RFD-KP6 with bacterial isolates. A) Fluorescent gel image of the paper microzones after cleavage reaction with the samples (sample ID is shown above each microzone). B) Graph of the quantified fluorescent signal obtained from the paper microzones in A. The error bars represent standard deviation of triplicate experiments. C) A representative dPAGE gel image of the reaction mixture of each bacterial sample of the paper microzones of A. Unclv: Uncleaved intact full length DNAzyme sequence, Clv: cleaved product of the DNAzyme after the reaction. The name of the bacteria of each sample ID is provided in Table S2 in SI and the isolates of *K. pneumoniae* are designated by an asterisk.